Tocilizumab Mitigates Immune Checkpoint Inhibitor–Induced Colitis and Inhibits Tumor Growth by Targeting the IL‐6‐JAK2‐STAT3 Signaling Pathway
Journal of Gastroenterology and Hepatology · 2026
DOI: 10.1111/jgh.70293 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Yanxin Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, H…. Hauptthemen laut MEDLINE: Janus Kinase 2, STAT3 Transcription Factor, Immune Checkpoint Inhibitors, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Changsha Natural Science Foundation, Hunan Provincial Natural Science Foundation of China.
Abstract (Originalsprache)
Intestinal adverse effects induced by immune checkpoint inhibitors (ICIs) during oncology treatment reduce patients' quality of life and limit the clinical application of ICIs. To elucidate the pathogenesis of ICI‐associated colitis and explore potential therapeutic strategies, we established a mouse model of PD‐1 inhibitor‐induced colitis. Utilizing a comprehensive suite of experimental techniques, including RNA sequencing, single‐cell RNA sequencing data analysis, hematoxylin–eosin (HE) staining, immunohistochemistry (IHC), enzyme‐linked immunosorbent assay (ELISA), Western blot (WB), small‐animal in vivo imaging, and tumor cell function assays, we demonstrated that IL‐6 is highly upregulated in the colitis mouse model. Moreover, the IL‐6‐JAK2‐STAT3 signaling pathway was significantly enriched, and the expression of proteins involved in this pathway was reduced following the addition of tocilizumab. This led to a decrease in colonic inflammation and a slowing of tumor growth. Therefore, we conclude that tocilizumab may attenuate PD‐1 inhibitor‐associated colonic inflammation and coinhibit tumor growth by targeting the IL‐6‐JAK2‐STAT3 pathway, providing new insights for clinical treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiotherapy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, Hunan Province, China.
- Department of Medical Genetics, Hunan Jiahui Genetics Hospital, Changsha, China.
ORCID-Profile: Yanxin Chen
Förderung
- Changsha Natural Science Foundation
- Hunan Provincial Natural Science Foundation of China
Zitieren
APA
Chen, Y., Wang, Y., Hu, Y., Luo, L., Yang, W., Li, Y., & Peng, Q. (2026). Tocilizumab Mitigates Immune Checkpoint Inhibitor–Induced Colitis and Inhibits Tumor Growth by Targeting the IL‐6‐JAK2‐STAT3 Signaling Pathway. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70293
Vancouver
Chen Y, Wang Y, Hu Y, Luo L, Yang W, Li Y, et al. Tocilizumab Mitigates Immune Checkpoint Inhibitor–Induced Colitis and Inhibits Tumor Growth by Targeting the IL‐6‐JAK2‐STAT3 Signaling Pathway. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70293
BibTeX
@article{Chen2026,
author = {Chen, Yanxin and Wang, Yong and Hu, Ying and Luo, Lingrong and Yang, Wenjuan and Li, Yu and Peng, Qian},
title = {Tocilizumab Mitigates Immune Checkpoint Inhibitor–Induced Colitis and Inhibits Tumor Growth by Targeting the IL‐6‐JAK2‐STAT3 Signaling Pathway},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
doi = {10.1111/jgh.70293}
}
EUVIMED